Black or African American patients have a higher ... Molecular profiles of patient tumors were determined from the Tempus multimodal database, through collaboration between Dr. Huang’s team ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the ...
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback